Aytu BioPharma, Inc.
AYTUHealthcare|Drug Manufacturers - Specialty & Generic|US
$1.83
+0.02 (+1.10%)
Cash / Share
$2.14
Financials
Financial Snapshot
Market Cap
$19.9M
Enterprise Value
$11.7M
Revenue (TTM)
$57.6M
Net Income (TTM)
-$14.3M
Cash & Investments
$26.3M
Net Cash
$8.2M
Free Cash Flow (TTM)
$3.3M
Operating CF (TTM)
$3.3M
Debt/Equity
0.51
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $802.3K | $7.0M | $11.0M | $48.1M | $49.6M | $19.4M | $23.0M | $20.0M | $31.0M | $26.3M | $26.3M | |
| Operating Cash Flow | -$13.8M | -$15.9M | -$13.8M | -$28.4M | -$26.0M | -$28.8M | -$5.1M | -$1.4M | -$1.9M | $3.3M | $3.3M | |
| Free Cash Flow | -$13.9M | -$16.0M | -$13.9M | -$28.4M | -$26.0M | -$28.8M | -$5.1M | -$1.7M | -$5.2M | $3.3M | $3.3M | |
| Capital Expenditure | -$111.6K | -$74.7K | -$59.8K | $0.00 | $0.00 | $0.00 | $0.00 | -$329.0K | -$3.2M | -$29.0K | -$29.0K | |
| Financing Cash Flow | $10.2M | $22.7M | $19.1M | $71.1M | $30.3M | $1.5M | $8.9M | -$1.3M | $15.4M | -$7.9M | -$7.9M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2M | $3.7M | $7.3M | $27.6M | $65.6M | $96.7M | $107.4M | $65.2M | $66.4M | $57.6M | $57.6M | |
| Cost of Revenue | $1.4M | $2.1M | $2.2M | $8.3M | $36.4M | $46.4M | $40.8M | $16.1M | $20.6M | $20.8M | $20.8M | |
| Gross Profit | $1.8M | $1.6M | $5.1M | $19.4M | $29.2M | $50.3M | $66.6M | $49.1M | $45.8M | $36.8M | $36.8M | |
| R&D | $1.3M | $167.6K | $589.1K | $1.7M | $5.6M | $12.7M | $4.1M | $2.8M | $1.3M | $0.00 | $0.00 | |
| SG&A | $17.6M | $17.7M | $19.2M | $31.1M | $55.8M | $69.9M | $70.1M | $42.0M | $38.3M | $42.6M | $42.6M | |
| Operating Income | -$20.1M | -$19.7M | -$16.8M | -$21.1M | -$58.9M | -$109.9M | -$17.1M | -$1.6M | -$7.8M | -$8.3M | -$8.3M | |
| Interest Expense | $2.5M | $749.4K | $0.00 | $0.00 | $0.00 | $147.5M | $5.0M | $4.8M | $3.7M | -$1.9M | $1.1M | |
| Pretax Income | -$22.5M | -$10.2M | -$27.1M | -$13.6M | -$58.0M | -$108.9M | -$17.1M | -$10.4M | -$13.7M | -$14.2M | -$14.2M | |
| Net Income | -$22.5M | -$10.2M | -$47.2M | -$13.6M | -$58.3M | -$108.8M | -$17.1M | -$15.8M | -$13.6M | -$14.3M | -$14.3M | |
| EPS (Diluted) | -193194.38 | -3061.23 | -1210.28 | -60.20 | -69.60 | -74.01 | -5.11 | -2.86 | -2.16 | -1.16 | -1.66 | |
| EBITDA | -$15.6M | -$15.3M | -$14.1M | -$12.2M | -$29.0M | -$28.0M | -$3.3M | $1.4M | -$4.7M | -$4.4M | -$8.5M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.04 | 0.23 | 0.84 | 1.47 | 3.34 | 5.54 | 6.28 | 12.32 | 12.32 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $802.3K | $7.0M | $11.0M | $48.1M | $49.6M | $19.4M | $23.0M | $20.0M | $31.0M | $26.3M | $26.3M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $3.0M | $9.5M | $15.4M | $75.4M | $105.2M | $59.9M | $72.8M | $61.9M | $79.2M | $61.8M | $61.8M | |
| Total Assets | $15.0M | $21.1M | $34.7M | $153.3M | $265.7M | $137.6M | $137.8M | $118.9M | $124.2M | $105.0M | $105.0M | |
| Total Current Liabilities | $3.6M | $3.4M | $5.4M | $28.8M | $109.4M | $64.4M | $69.0M | $62.2M | $63.1M | $54.7M | $54.7M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $2.8M | $14.2M | $20.9M | $10.9M | $10.9M | $9.1M | $9.1M | |
| Total Liabilities | $11.0M | $7.6M | $27.6M | $58.3M | $128.1M | $93.3M | $98.5M | $91.1M | $105.2M | $69.7M | $69.7M | |
| Stockholders' Equity | $4.0M | $13.4M | $7.1M | $95.0M | $137.6M | $44.3M | $39.4M | $27.7M | $19.0M | $35.3M | $35.3M | |
| Retained Earnings | -$69.1M | -$79.3M | -$106.4M | -$120.0M | -$178.3M | -$287.1M | -$304.1M | -$320.0M | -$333.5M | -$347.8M | -$347.8M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.8M | -$15.9M | -$13.8M | -$28.4M | -$26.0M | -$28.8M | -$5.1M | -$1.4M | -$1.9M | $3.3M | $3.3M | |
| Capital Expenditure | -$111.6K | -$74.7K | -$59.8K | $0.00 | $0.00 | $0.00 | $0.00 | -$329.0K | -$3.2M | -$29.0K | -$29.0K | |
| Free Cash Flow | -$13.9M | -$16.0M | -$13.9M | -$28.4M | -$26.0M | -$28.8M | -$5.1M | -$1.7M | -$5.2M | $3.3M | $3.3M | |
| Investing Cash Flow | -$3.5M | -$484.3K | -$1.1M | -$5.7M | -$2.8M | -$3.2M | -$117.0K | -$329.0K | -$2.6M | -$29.0K | -$29.0K | |
| Financing Cash Flow | $10.2M | $22.7M | $19.1M | $71.1M | $30.3M | $1.5M | $8.9M | -$1.3M | $15.4M | -$7.9M | -$7.9M | |
| Issuance of Stock | $9.3M | $248.4K | $11.7K | $65.7M | $40.1M | $11.7M | $15.6M | $3.5M | $14.8M | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $5.0M | -$16.2M | -$3.7M | -$5.2M | -$2.3M | -$1.9M | $6.7M | -$7.9M | -$4.8M | |
| Stock Based Comp. | $2.5M | $348.5K | $1.0M | $1.1M | $3.6M | $5.2M | $6.0M | $2.4M | $576.0K | $691.0K | $691.0K | |
| Net Change in Cash | -$7.2M | $6.2M | $4.2M | $37.0M | $1.6M | -$30.5M | $3.6M | -$3.0M | $10.9M | -$4.6M | -$4.6M |
Dilution Tracker
Shares outstanding grew 1366.5% over 5 years — significant dilution
Shares Outstanding
11M
5-Year Share Growth
+1366.5%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.04 | 0.23 | 0.84 | 1.47 | 3.34 | 5.54 | 6.28 | 12.32 | 12.32 | |
| Change vs Prior % | — | 2744.4% | 1071.0% | 490.2% | 265.2% | 75.0% | 127.2% | 65.8% | 13.4% | 96.2% | 0.0% | |
| Stock Issuance | $9.3M | $248.4K | $11.7K | $65.7M | $40.1M | $11.7M | $15.6M | $3.5M | $14.8M | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $2.5M | $348.5K | $1.0M | $1.1M | $3.6M | $5.2M | $6.0M | $2.4M | $576.0K | $691.0K | $691.0K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 56.0% | 44.0% | 69.9% | 70.0% | 44.5% | 52.0% | 62.0% | 75.3% | 69.0% | 64.0% | 64.0% | |
| Operating Margin % | -624.7% | -538.3% | -230.1% | -76.5% | -89.7% | -113.7% | -15.9% | -2.4% | -11.8% | -14.4% | -14.4% | |
| Net Margin % | -698.7% | -278.4% | -644.3% | -49.3% | -88.8% | -112.5% | -15.9% | -24.3% | -20.4% | -24.8% | -24.8% | |
| EBITDA Margin % | -484.5% | -416.7% | -192.9% | -44.2% | -44.2% | -28.9% | -3.0% | 2.2% | -7.0% | -7.6% | -14.7% | |
| FCF Margin % | -432.7% | -437.6% | -189.8% | -102.7% | -39.6% | -29.8% | -4.8% | -2.6% | -7.8% | 5.6% | 5.6% | |
| ROE % | -562.7% | -75.9% | -665.5% | -14.3% | -42.4% | -245.5% | -43.3% | -57.2% | -71.5% | -40.4% | -52.9% | |
| ROA % | -150.1% | -48.4% | -135.8% | -8.9% | -21.9% | -79.0% | -12.4% | -13.3% | -10.9% | -13.6% | -13.6% | |
| ROIC % | -176.7% | -111.5% | -57.4% | -16.8% | -32.4% | -142.4% | -22.0% | -2.6% | -10.8% | -14.2% | -14.2% | |
| R&D / Revenue % | 41.8% | 4.6% | 8.0% | 6.2% | 8.6% | 13.1% | 3.8% | 4.2% | 2.0% | 0.0% | 0.0% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.7% | 13.6% | 100.0% | 277.5% | 137.5% | 47.3% | 11.1% | -39.3% | 1.8% | -13.3% | |
| Gross Profit | 12.4% | -10.8% | 218.0% | 278.1% | 50.9% | 72.2% | 32.5% | -26.4% | -6.6% | -19.7% | |
| Operating Income | 7.3% | 2.1% | 14.5% | -25.4% | -178.6% | -86.7% | 84.5% | 90.7% | -392.0% | -6.2% | |
| Net Income | 20.1% | 54.7% | -363.0% | 71.1% | -327.9% | -86.6% | 84.3% | 7.1% | 14.4% | -5.1% | |
| EPS (Diluted) | 85.1% | 98.4% | 60.5% | 95.0% | -15.6% | -6.3% | 93.1% | 44.0% | 24.5% | 46.3% | |
| Operating Cash Flow | -29.8% | -15.3% | 13.2% | -105.1% | 8.5% | -11.0% | 82.2% | 72.9% | -39.6% | 269.4% | |
| Free Cash Flow | -8.0% | -14.9% | 13.3% | -104.3% | 8.5% | -11.0% | 82.2% | 66.5% | -200.8% | 163.0% | |
| R&D Expense | -78.7% | -87.6% | 251.5% | 192.3% | 226.5% | 125.2% | -67.7% | -32.4% | -52.1% | -100.0% | |
| SG&A Expense | 99.5% | 0.7% | 8.5% | 61.4% | 79.7% | 25.2% | 0.3% | -40.0% | -8.9% | 11.4% | |
| Total Assets | -38.4% | 40.4% | 64.9% | 341.5% | 73.3% | -48.2% | 0.2% | -13.8% | 4.5% | -15.4% | |
| Book Value / Share | -92.5% | -88.2% | -95.5% | 127.1% | -60.4% | -81.6% | -60.9% | -57.5% | -39.7% | -5.2% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 1443.1% | -41.3% | 67.3% | -46.0% | 39.7% | -21.1% | |
| Diluted Shares | 431.8% | 2744.4% | 1071.0% | 490.2% | 265.2% | 75.0% | 127.2% | 65.8% | 13.4% | 96.2% |
Valuation
P/E (TTM)At Loss
P/S0.35
10Y Low / Med / High0.05 / 0.95 / 2.36
P/B0.64
10Y Low / Med / High0.14 / 0.69 / 2.11
EV/EBITDAAt Loss
EV/Revenue0.20
10Y Low / Med / High0.09 / 0.32 / 1.47
P/FCF6.12
Intrinsic Value Models (per share)
Cash / Share
$2.14
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.24 | -0.34 | -0.32 | -4.72 | -1.44 | -0.19 | -0.31 | -1.00 | -1.01 | -1.85 | -1.33 | |
| P/S Ratio | 1.71 | 0.95 | 2.04 | 2.36 | 1.28 | 0.21 | 0.05 | 0.24 | 0.21 | 0.46 | 0.35 | |
| P/B Ratio | 1.38 | 0.26 | 2.11 | 0.69 | 0.61 | 0.46 | 0.14 | 0.57 | 0.72 | 0.75 | 0.64 | |
| EV/EBITDA | -0.30 | 0.23 | -0.28 | -1.58 | -2.26 | -0.68 | -3.91 | 8.67 | -1.22 | -4.17 | -1.38 | |
| EV/Revenue | 1.47 | -0.97 | 0.54 | 0.70 | 1.00 | 0.20 | 0.12 | 0.19 | 0.09 | 0.32 | 0.20 |
Analyst Estimates & Quality
Altman Z-Score
-4.23
Distress
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2027 | FY2028 | FY2029 |
|---|---|---|---|
| Revenue | $67.9M | $86.9M | $116.2M |
| Net Income | -$7.6M | $3.3M | $19.7M |
| EPS | $-0.62 | $0.27 | $1.60 |
| # Analysts (EPS) | 1 | 1 | 1 |
Revenue Segments
By Product
| Segment | 2017 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| AYTU Bioscience, Inc. | $3.2M | — | — | — | — | — |
| Aytu Women's Health | $47.0K | — | — | — | — | — |
| License Revenue | — | — | — | — | — | — |
| Product Revenue | — | $27.6M | — | — | — | — |
| Aytu Bio Pharma | — | — | $32.7M | — | — | — |
| Aytu Consumer Health | — | — | $33.0M | — | — | — |
| Consumer Health Portfolio | — | — | — | $35.5M | — | — |
| Pediatric Portfolio | — | — | — | $16.1M | — | — |
| Consumer Health | — | — | — | — | $33.6M | $15.8M |
By Geography
| Segment | 2015 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| KOREA, REPUBLIC OF | $500.0K | — | — | — | — |
| Non Us | — | $4.9M | — | — | — |
| Non-US | — | — | $2.1M | $481.0K | $91.0K |
| UNITED STATES | — | — | $94.6M | $106.9M | $80.9M |